Immune Network Research ( IMM-V ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Immune Network Research ( IMM-V )

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Al Viegut who wrote (17)	4/3/1997 2:01:00 PM
From: John	of 57

To all. Here an April 2/3 news release from IMM!! Michael D. Grant, Director of Immune Network Research Ltd., announces that further research related to the safety/feasibility study of CTB-1 in on-human primates macaque mulata revealed that CTB-1 injection increased virus-neutralizing antibody levels in monkeys chronically infected with SHIV(IIIB). SHIV(IIIB) is a recombinant retrovirus designed to allow study of anti-HIV immune responses in macaque monkeys. This work was carried out by Drs. Sybille Muller and Heinz Kohler of the University of Kentucky in collaboration with scientists at the New England Regional Primate Center and the US National Cancer Institute. The Company is also pleased to report that the US Patent office has given notice of allowance of certain patent claims on the monoclonal antibody CTB-1 and its use in respect of HIV infection. Laboratory analysis of plasma samples taken from the macaques receiving CTB-1 demonstrated a rapid rise in the potency of antibody neutralization of HIV(IIIB) and HIV(MN) following CTB-1 injection. This indicates that CTB-1 stimulated de novo production of broadly neutralizing anti-HIV antibodies in the infected macaques. Studies are now underway to test whether monkeys that have developed symptoms of retrovirus-induced immunodeficiency benefit from CTB-1 injection in terms of lower virus load, lymphocyte subset normalization or longer disease free survival. If results from these next studies are favourable, the Company would proceed to seek approval for clinical trials to determine if CTB-1 has beneficial effect on the immune system and on disease progression in human HIV infection. The Company has engaged the services of Drs. Muller and Kohler through Immpheron, Inc. to produce more CTB-1 monoclonal antibody, continue the macaque studies and coordinate the research with collaborating scientists. On corporate matters, the Board of Directors is continuing its due diligence with respect to the proposed business combination with Bio-Fluorescent Technologies, Inc., a public United States company, in preparation for consideration of this matter the upcoming Annual General Meeting. Trading of the Company's shares remains halted at the request of the Vancouver Stock Exchange pending necessary shareholder and regulatory approvals of the transaction. For additional information please contact The Genesis Group TEL: (604) 689-3923 Michael D. Grant, Director FAX: (604) 684-5854

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next